Biotech is benefiting from belt-tightening, but some pain still to come — Bruce Booth 

Bruce Booth believes the belt-tightening of the past few years will presage a better financing outlook for biotechs, but the ripple effects will be felt for some time to come.

The Atlas Venture partner told The BioCentury Show there are clear positive signs for biotech, with the XBI bouncing back from its low in the mid-60s, February’s robust follow-on activity — one of the largest ever, he said, including PIPEs and other transactions — and a stream of M&A deals. “The billions of capital that’s been returned to specialist investors now is recycling into the ecosystem,” he said. ...